Clinical Trial Diversity in Focus
Unable to add items
Sorry, we're unable to add the item because your cart is already full.
Add to basket failed.
Please try again later
Add to wishlist failed.
Please try again later
Failed to remove from Wish List.
Please try again later
Adding to library failed
Please try again
Unable to follow podcast
Unable to unfollow podcast
-
Narrated by:
-
By:
Summary
On this episode of Ropes & Gray’s podcast series Non-binding Guidance, health care partner David Peloquin and life sciences regulatory and compliance counsel Sarah Blankstein discuss the FDA's recent draft guidance on diversity action plans (DAPs) aimed at improving the enrollment of underrepresented populations in clinical studies. They examine the implications and challenges sponsors may face in setting and meeting enrollment goals, as well as the potential impact of the recent presidential election on the final guidance. They also address key open questions related to the draft guidance.
adbl_web_anon_alc_button_suppression_t1
No reviews yet